000			02048 a2200601 4500
005			20250517045008.0
264		0	_c20160524
008			201605s 0 0 eng d
022			_a1949-2553
024	7		_a10.18632/oncotarget.4641 _2doi
040			_aNLM _beng _cNLM
100	1		_aWang, Min
245	0	0	_aElevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma. _h[electronic resource]
260			_bOncotarget _cJul 2015
300			_a17958-67 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBasic Helix-Loop-Helix Transcription Factors _xgenetics
650	0	4	_aBiomarkers, Tumor _xblood
650	0	4	_aCD4 Lymphocyte Count
650	0	4	_aCase-Control Studies
650	0	4	_aChina
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInterferon-gamma _xblood
650	0	4	_aInterleukin-17 _xblood
650	0	4	_aInterleukins _xblood
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultiple Myeloma _xblood
650	0	4	_aNeoplasm Staging
650	0	4	_aNuclear Receptor Subfamily 1, Group F, Member 3 _xgenetics
650	0	4	_aPolymerase Chain Reaction
650	0	4	_aRNA, Messenger _xmetabolism
650	0	4	_aReceptors, Aryl Hydrocarbon _xgenetics
650	0	4	_aRemission Induction
650	0	4	_aT-Lymphocyte Subsets _xdrug effects
650	0	4	_aTh17 Cells _xdrug effects
650	0	4	_aTreatment Outcome
650	0	4	_aInterleukin-22
700	1		_aChen, Ping
700	1		_aJia, Yan
700	1		_aHe, Na
700	1		_aLi, Daqi
700	1		_aJi, Chunyan
700	1		_aMa, Daoxin
773	0		_tOncotarget _gvol. 6 _gno. 20 _gp. 17958-67
856	4	0	_uhttps://doi.org/10.18632/oncotarget.4641 _zAvailable from publisher's website
999			_c25152130 _d25152130